As a clinical-stage biotech company, CytoAgents is making tremendous strides in the battle against Cytokine Release Syndrome (CRS), a dangerous overreaction of the immune system. Our drug candidate will increase patient safety and make important treatments such as CAR T-cell therapy safer for patients. We invite you to join us as we move closer to our goal. Follow our progress here: https://cytoagents.com/ #cytokinereleasesyndrome #cytokines #crs #cartcelltherapy Teresa Whalen, RPh
